Tetratherix CEO Will Knox joins Proactive's Fouad Haidar live from the ASX Small and Mid Cap Conference. Tetratherix is an Australian medical technology company developing advanced biomaterial solutions to transform the treatment of complex diseases. Its proprietary polymer platform enables the targeted delivery of cells, drugs, and biologics, opening new opportunities across oncology, regenerative medicine, and related fields.
The company combines scientific innovation with clinical impact, supported by a business model designed for global scalability and collaboration with healthcare partners worldwide. At the core of Tetratherix’s portfolio is Tetramatrix™, a safe and clinically modular technology platform. Its versatility allows for the co-development of multiple products in partnership with leading medical companies. The aim is to provide patients with treatments that are faster, safer, and more cost-effective.
Product franchises
Tetratherix is advancing a portfolio of near-term commercial opportunities using the Tetramatrix™ platform across three key areas:
1. Bone regeneration: developing products to support bone repair in dental and orthopaedic applications.
2. Tissue spacing: creating products that generate space between tissues or organs, either to improve surgical access in ophthalmic procedures or to minimise side effects during cancer treatment.
3. Tissue healing: producing solutions for use during open surgical interventions to reduce scar formation at incision sites.